INS and metabolic syndrome: This altered interplay between insulin sensitivity and secretion, in turn, leads to and/or exacerbates lipid and carbohydrate substrate imbalance and is instrumental for the development not only of type 2 diabetes, but also atherogenic dyslipidemia (characterized by high triglycerides and low high-density lipoprotein (HDL)-cholesterol levels) and all the additional abnormalities of the constellation described above [19,27,28,29].